Debanjan Ray, Synthekine CEO
January 29, 2024 08:00 AM ESTUpdated January 31, 06:26 AM
Deals

Sanofi part­ners with Syn­thekine in im­munol­o­gy race

Katherine Lewin

News Reporter

Syn­thekine is team­ing up with Sanofi in a $40 mil­lion-plus col­lab­o­ra­tion to de­vel­op IL-10 re­cep­tor ag­o­nists for au­toim­mune and in­flam­ma­to­ry dis­eases.

The cy­tokine-fo­cused biotech will …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Among phar­ma CEOs, the IRA now and the IRA lat­er get very dif­fer­ent re­ac­tions

Bris­tol My­ers restarts ra­dio­phar­ma­ceu­ti­cal Phase 3 tri­al, but de­lays read­out by one year

An­drew Left, short sell­er who cam­paigned against Valeant, is ac­cused of fraud by SEC

Up­dat­ed: With cost-cut­ting un­der­way, Bris­tol My­ers rais­es guid­ance, touts Phase 3 win and scraps an­oth­er

Eu­ro­pean drug reg­u­la­tor re­jects Alzheimer's drug Leqem­bi, cit­ing safe­ty con­cerns

sponsored

Crit­i­cal Junc­tures in Gene Ther­a­py Clin­i­cal Ma­te­r­i­al Man­u­fac­tur­ing: Where Do I Start? And Will It Work?

A service from the Financial Times